Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2019

Open Access 01-04-2019 | Esophageal Cancer | Thoracic Oncology

Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer

Authors: Z. Faiz, MD, M. van Putten, PhD, R. H. A. Verhoeven, PhD, J. W. van Sandick, MD, PhD, G. A. P. Nieuwenhuijzen, MD, PhD, M. J. C. van der Sangen, MD, V. E. P. P. Lemmens, PhD, B. P. L. Wijnhoven, MD, PhD, J. T. M. Plukker, MD, PhD

Published in: Annals of Surgical Oncology | Issue 4/2019

Login to get access

Abstract

Purpose

This study was designed to assess the impact of age and comorbidity on choice and outcome of definitive chemoradiotherapy (dCRT) or neoadjuvant chemoradiotherapy plus surgery.

Methods

In this population-based study, all patients with potentially curable EC (cT1N+/cT2-3, TX, any cN, cM0) diagnosed in the South East of the Netherlands between 2004 and 2014 were included. Kaplan–Meier method with log-rank tests and multivariable Cox regression analysis were used to compare overall survival (OS).

Results

A total of 702 patients was included. Age ≥ 75 years and multiple comorbidities were associated with a higher probability for dCRT (odds ratio [OR] 8.58; 95% confidence interval [CI] 4.72–15.58; and OR 3.09; 95% CI 1.93–4.93). The strongest associations were found for the combination of hypertension plus diabetes (OR 3.80; 95% CI 1.97–7.32) and the combination of cardiovascular with pulmonary comorbidity (OR 3.18; 95% CI 1.57–6.46). Patients with EC who underwent dCRT had a poorer prognosis than those who underwent nCRT plus surgery, irrespective of age, number, and type of comorbidities. In contrast, for patients with squamous cell carcinoma with ≥ 2 comorbidities or age ≥ 75 years, OS was comparable between both groups (hazard ratio [HR] 1.52; 95% CI 0.78–2.97; and HR 0.73; 95% CI 0.13–4.14).

Conclusions

Histological tumor type should be acknowledged in treatment choices for patients with esophageal cancer. Neoadjuvant chemoradiotherapy plus surgery should basically be advised as treatment of choice for operable esophageal adenocarcinoma patients. For patients with esophageal squamous cell carcinoma with ≥ 2 comorbidities or age ≥ 75 years, dCRT may be the preferred strategy.
Literature
1.
van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.CrossRefPubMed
2.
Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T. Definitive chemoradiation for esophageal cancer-a standard of care in patients with non-metastatic esophageal cancer. Clin Oncol (R Coll Radiol). 2011;23(3):182–8.CrossRef
3.
Morgan MA, Lewis WG, Casbard A, Roberts SA, Adams R, Clark GW et al. Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for esophageal carcinoma. Br J Surg. 2009;96(11):1300–7.CrossRefPubMed
4.
In H, Palis BE, Merkow RP, Posner MC, Ferguson MK, Winchester DP et al. Doubling of 30-day mortality by 90 days after esophagectomy: a critical measure of outcomes for quality improvement. Ann Surg. 2016;263(2):286–91.CrossRefPubMed
5.
Walters DM, McMurry TL, Isbell JM, Stukenborg GJ, Kozower BD. Understanding mortality as a quality indicator after esophagectomy. Ann Thorac Surg. 2014;98(2):506–11.CrossRefPubMed
6.
Pultrum BB, Bosch DJ, Nijsten MW, Rodgers MG, Groen H, Slaets JP, Plukker JT. Extended esophagectomy in elderly patients with esophageal cancer: minor effect of age alone in determining the postoperative course and survival. Ann Surg Oncol. 2010;17(6):1572–80.CrossRefPubMedPubMedCentral
7.
van Gestel YR, Lemmens VE, de Hingh IH, Steevens J, Rutten HJ, Nieuwenhuijzen GA, et al. Influence of comorbidity and age on 1-, 2-, and 3-month postoperative mortality rates in gastrointestinal cancer patients. Ann Surg Oncol. 2013;20(2):371–80.CrossRefPubMed
8.
Koppert LB, Lemmens VE, Coebergh JW, Steyerberg EW, Wijnhoven BP, Tilanus HW, et al. Impact of age and co-morbidity on surgical resection rate and survival in patients with esophageal and gastric cancer. Br J Surg. 2012;99(12):1693–700.CrossRefPubMed
9.
Chuang WY, Yeh CJ, Wu YC, Chao YK, Liu YH, Tseng CK, et al. Tumor cell expression of podoplanin correlates with nodal metastasis in esophageal squamous cell carcinoma. Histol Histopathol. 2009;24(8):1021–7.PubMed
10.
Muijs CT, Beukema JC, Mul VE, Plukker JT, Sijtsema NM, Langendijk JA. External beam radiotherapy combined with intraluminal brachytherapy in esophageal carcinoma. Radiother Oncol. 2012;102(2):303–8.CrossRefPubMed
11.
Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310–7.CrossRefPubMed
12.
Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.CrossRefPubMed
13.
Tougeron D, Scotté M, Hamidou H, Di Fiore F, Paillot B, Michot F, Michel P. Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery? J Surg Oncol. 2012;105(8):761–6.CrossRefPubMed
14.
Murphy CC, Correa AM, Ajani JA, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg. 2013;17(8):1359–69.CrossRefPubMedPubMedCentral
15.
Créhange G, Conroy T. The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future? J Thorac Dis. 2016;8(6):1014–8.CrossRefPubMedPubMedCentral
16.
Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50–7.CrossRefPubMed
17.
Kristjansson SR, Nesbakken A, Jordhøy MS, Skovlund E, Audisio RA, Johannessen HO, et al. Comprehensive geriatric assessment can predict complications in elderly patients after elective surgery for colorectal cancer: a prospective observational cohort study. Crit Rev Oncol Hematol. 2010;76(3):208–17.CrossRefPubMed
18.
van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, Tran TC, van der Gaast A. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer. 2006;94(10):1389–94.CrossRefPubMedPubMedCentral
19.
Markar S, Gronnier C, Duhamel A, et al. Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option? J Clin Oncol. 2015;33:3866–73.CrossRefPubMed
20.
21.
Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol. 2005;55(3):231–40.CrossRefPubMed
22.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed
23.
Bosch DJ, Pultrum BB, de Bock GH, Oosterhuis JK, Rodgers MG, Plukker JT. Comparison of different risk-adjustment models in assessing short-term surgical outcome after transthoracic esophagectomy in patients with esophageal cancer. Am J Surg. 2011;202(3):303–9.CrossRefPubMed
24.
Rothman KJ, Greenland S, eds. Modern epidemiology, 2nd edn. Philadelphia: Lippincott-Raven, 1998. pp. 79–91.
25.
Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for esophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.CrossRefPubMed
26.
Sabel MS, Smith JL, Nava HR, Mollen K, Douglass HO, Gibbs JF. Esophageal resection for carcinoma in patients older than 70 years. Ann Surg Oncol. 2002;9:210–4.CrossRefPubMed
27.
Cronin-Fenton DP, Sharp L, Carsin AE, Comber H. Patterns of care and effects on mortality for cancers of the oesophagus and gastric cardia: a population-based study. Eur J Cancer. 2007;43:565–75.CrossRefPubMed
28.
Stairmand J, Signal L, Sarfati D, Jackson C, Batten L, Holdaway M, et al. Consideration of co-morbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic review. Ann Oncol. 2015;26(7):1325–32.CrossRefPubMed
29.
30.
Rebecca WO, Richard MA. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev. 2003;(1):CD002092.
31.
Wong RK, Malthaner RA, Zuraw L, Rumble RB. Cancer Care Ontario Practice Guidelines Initiative Gastrointestinal Cancer Disease Site Group. Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: a practice guideline. Int J Radiat Oncol Biol Phys. 2003;55(4):930–42.CrossRefPubMed
32.
Koppert LB, Lemmens VE, Coebergh JW, Steyerberg EW, Wijnhoven BP, Tilanus HW, et al. Impact of age and co-morbidity on surgical resection rate and survival in patients with esophageal and gastric cancer. Br J Surg. 2012;99(12):1693–700.CrossRefPubMed
33.
Muijs C, Smit J, Karrenbeld A, Beukema J, Mul V, van Dam G, Hospers G, Kluin P, Langendijk J, Plukker J. Residual tumor after neoadjuvant chemoradiation outside the radiation therapy target volume: a new prognostic factor for survival in esophageal cancer. Int J Radiat Oncol Biol Phys. 2014;88(4):845–52.CrossRefPubMed
34.
Kole TP, Aghayere O, Kwah J, Yorke ED, Goodman KA. Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1580–6.CrossRefPubMed
35.
Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, et al. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumours: a dosimetric study. Int J Radiat Oncol Biol Phys. 2011;81(5):1336–42.CrossRefPubMedPubMedCentral
36.
Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107:267–73.CrossRefPubMed
37.
Honing J, Smit JK, Muijs CT, Burgerhof JG, de Groot JW, Paardekooper G, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in EC patients. Ann Oncol. 2014;25(3):638–43.CrossRefPubMedPubMedCentral
38.
Faiz Z, Van Putten M, Verhoeven RHA et.al. Impact of comorbidity in the choice of curative treatment for esophageal cancer: a population-based study. JCO. 2016 34(4_suppl):131.CrossRef
Metadata
Title
Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer
Authors
Z. Faiz, MD
M. van Putten, PhD
R. H. A. Verhoeven, PhD
J. W. van Sandick, MD, PhD
G. A. P. Nieuwenhuijzen, MD, PhD
M. J. C. van der Sangen, MD
V. E. P. P. Lemmens, PhD
B. P. L. Wijnhoven, MD, PhD
J. T. M. Plukker, MD, PhD
Publication date
01-04-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 4/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07181-6

Other articles of this Issue 4/2019

Annals of Surgical Oncology 4/2019 Go to the issue

Gastrointestinal Oncology

Should Multidisciplinary Treatment Differ for Esophageal Adenocarcinoma Versus Esophageal Squamous Cell Cancer?

Thoracic Oncology

The Role and Prognostic Significance of Aortopulmonary, Anterior Mediastinal, and Tracheobronchial Lymph Nodes in Esophageal Cancer: Update of the Eighth-Edition TNM Staging System (2018)

Colorectal Cancer

Impact of Family History on Prognosis of Patients with Sporadic Colorectal Cancer

Peritoneal Surface Malignancy

Characterizing the Patient Experience of CS/HIPEC Through In-Depth Interviews with Patients: Identification of Key Concepts in the Development of a Patient-Centered Program

Breast Oncology

Do Internal Mammary Nodes Matter?

Pancreatic Tumors

Endoscopic Retrograde Biliary Drainage Causes Intra-Abdominal Abscess in Pancreaticoduodenectomy Patients: An Important But Neglected Risk Factor